Study Finds Repeat Dosing of IVIG and PLEX Common in GBS, Resulting in Harm to Nonresponders
According to randomized controlled trials, repeat intravenous immune globulin (IVIG) dosing and plasma exchange (PLEX) followed by IVIG (combination therapy) have no additional therapeutic benefit in Guillain-Barré syndrome (GBS) nonresponders. Furthermore, the delineation between GBS and acute onset chronic inflammatory demyelinating polyneuropathy (A-CIDP) can be particularly challenging and carries therapeutic implications. In the retrospective study […]
The Expanding Role of Immune Globulin Treatment in Diseases: Utilization and Growth
New research showing the therapeutic benefit of immune globulin for treating a variety of autoimmune diseases is contributing to market growth of this essential medicine.
IVIG Reduces Symptom Severity for AGID
A new study indicates intravenous immun globulin (IVIG) therapy can reduce symptom severity for patients with autoimmune gastrointestinal dysmotility (AGID), also known as gastroparesis.
CSL Begins Enrollment for Hizentra Study for POTS
CSL Ltd. has begun enrolling U.S. patients in a Phase III late-stage randomized control trial to assess whether Hizentra subcutaneous immune globulin (SCIG) can alleviate symptoms of postural orthostatic tachycardia syndrome (POTS) — a blood circulation disorder that is one of the most common and disabling symptoms of long COVID with no approved therapies.
Addition of IVIG May Be Superior to Addition of Plasmapheresis in Corticosteroid-Resistant Optic Neuritis: Systemic Review
A meta-analysis and systematic review compared the efficacy of corticosteroids (CS) alone against CS combined with intravenous immune globulin (IVIG) or CS combined with plasmapheresis (PP) in patients with steroid-resistant optic neuritis.
Xembify Receives Expanded Label for PI Patients
The U.S. Food and Drug Administration (FDA) has approved an expanded label for Grifols’ XEMBIFY (20% subcutaneous immune globulin [SCIG]) to include treatment-naïve patients with primary humoral immunodeficiencies (PI).
The Proven Success of Immune Globulin Therapy to Treat Chronic Inflammatory Demyelinating Polyneuropathy
Numerous studies show the efficacy of both IVIG and SCIG for treating CIDP, making these the best treatment options for this rare neurological condition.
Combination of IVIG and Corticosteroids Superior to Respective Monotherapies for Treatment of Relapsed ITP in Adults
The combination of intravenous immune globulin (IVIG) and corticosteroids is a more efficient and rapid treatment for relapsed immune thrombocytopenic purpura (ITP) in adults compared with the use of either therapy alone.
IVIG May Improve Neurological Symptoms in MIS-C
Recent case series findings, as well as previous studies, show that children with multisystem inflammatory syndrome (MIS-C) who present with signs of active neurological symptoms may show improvement with intravenous immune globulin (IVIG) and corticosteroids.
High-Dose IVIG Reduces Mortality Risk in Hospitalized Patients with Severe COVID-19: Systematic Review and Meta-Analysis
A systematic search of leading databases and registries by Chinese collaborators compared the efficacy of IVIG to routine care for hospitalized COVID-19 patients.
